重新审视乳腺癌诊断至初次手术的时间
该病例系列研究利用美国国家癌症数据库2010-2014年女性I-III期导管或小叶乳腺癌患者数据,分析诊断至手术时间与总生存的关系。
要点
- 手术时间≥9周与更差总生存独立相关(HR 1.15)。
- 推荐8周以内作为手术及时性的质量指标。
- 年轻、无保险/医疗补助、低收入社区患者手术延迟风险更高。
核心结论
- 诊断至手术时间≥9周与更差总生存相关,建议以8周以内作为质量指标。
- 手术延迟超过8周可能部分与不利的社会健康决定因素相关。
研究设计与样本
- 病例系列研究,使用美国国家癌症数据库(NCDB)2010-2014年诊断的女性乳腺癌患者数据,随访至2019年。
- 纳入18岁以上I-III期导管或小叶乳腺癌且手术为首程治疗的患者,排除既往乳腺癌、受体信息缺失、接受新辅助或实验性治疗、诊断当日手术者。
- 最终队列包含373 334例患者,中位年龄61岁(IQR 51-70)。
主要发现
- 与手术时间1-30天相比,年轻患者(≤45岁)手术时间31-60天的调整OR为1.32(95%CI 1.28-1.38),61-74天为1.64(95%CI 1.52-1.78),>74天为1.58(95%CI 1.46-1.71)。
- 医疗补助(Medicaid)患者手术时间31-60天的调整OR为1.35(95%CI 1.30-1.39),61-74天为2.13(95%CI 2.01-2.26),>74天为3.42(95%CI 3.25-3.61)。
- 家庭收入低于38 000美元的患者手术时间31-60天的调整OR为1.35(95%CI 1.02-1.07),61-74天为1.21(95%CI 1.15-1.27),>74天为1.53(95%CI 1.46-1.61)。
临床怎么用
- 临床可参考8周以内作为乳腺癌诊断至手术的时间质量指标。
- 对年轻、无保险/医疗补助、低收入社区患者应关注手术延迟风险并优化流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although longer times from breast cancer diagnosis to primary surgery have been associated with worse survival outcomes, the specific time point after which it is disadvantageous to have surgery is unknown. Identifying an acceptable time to surgery would help inform patients, clinicians, and the health care system. OBJECTIVE: To examine the association between time from breast cancer diagnosis to surgery (in weeks) and overall survival and to describe factors associated with surgical delay. The hypothesis that there is an association between time to surgery and overall survival was tested. DESIGN, SETTING, AND PARTICIPANTS: This was a case series study that used National Cancer Database (NCDB) data from female individuals diagnosed with breast cancer from 2010 to 2014 (with 5-year follow-up to 2019). The NCDB uses hospital registry data from greater than 1500 Commission on Cancer-accredited facilities, accounting for 70% of all cancers diagnosed in the US. Included participants were females 18 years or older with stage I to III ductal or lobular breast cancer who underwent surgery as the first course of treatment. Patients with prior breast cancer, missing receptor information, neoadjuvant or experimental therapy, or who were diagnosed with breast cancer on the date of their primary surgery were excluded. Multivariable Cox regression was used to evaluate factors associated with overall survival. Patients were censored at death or last follow-up. Covariates included age and tumor characteristics. Multinomial regression was performed to identify factors associated with longer time to surgery, using surgery 30 days or less from diagnosis as the reference group. Data were analyzed from March 15 to July 7, 2022. EXPOSURES: Time to receipt of primary breast surgery. MEASURES: The primary outcome measure was overall survival. RESULTS: The final cohort included 373 334 patients (median [IQR] age, 61 [51-70] years). On multivariable Cox regression analysis, time to surgery 9 weeks (57-63 days) or later after diagnosis was associated with worse overall survival (hazard ratio, 1.15; 95% CI, 1.08-1.23; P < .001) compared with surgery between 0 to 4 weeks (1-28 days). By multinomial regression, factors associated with longer times to surgery (using surgery 1-30 days from diagnosis as a reference) included the following: (1) younger age, eg, the adjusted odds ratio (OR) for patients 45 years or younger undergoing surgery 31 to 60 days from diagnosis was 1.32 (95% CI, 1.28-1.38); 61 to 74 days, 1.64 (95% CI, 1.52-1.78); and greater than 74 days, 1.58 (95% CI, 1.46-1.71); (2) uninsured or Medicaid status, eg, the adjusted OR for patients with Medicaid undergoing surgery 31 to 60 days from diagnosis was 1.35 (95% CI, 1.30-1.39); 61 to 74 days, 2.13 (95% CI, 2.01-2.26); and greater than 74 days, 3.42 (95% CI, 3.25-3.61); and (3) lower neighborhood household income, eg, the adjusted OR for patients with household income less than $38,000 undergoing surgery 31 to 60 days from diagnosis was 1.35 (95% CI, 1.02-1.07); 61 to 74 days, 1.21 (95% CI, 1.15-1.27); and greater than 74 days, 1.53 (95% CI, 1.46-1.61). CONCLUSIONS AND RELEVANCE: Findings of this case series study suggest the use of 8 weeks or less as a quality metric for time to surgery. Time to surgery of greater than 8 weeks may partly be associated with disadvantageous social determinants of health.
引用
- Wiener AA, Hanlon BM, Schumacher JR, et al. Reexamining Time From Breast Cancer Diagnosis to Primary Breast Surgery. JAMA Surg. 2023. PMID: 36857045. doi:10.1001/jamasurg.2022.8388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。